# Evox Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evox-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.evoxtherapeutics.com
- Total disclosed funding: $157M
- Latest round: Series C (Feb 18, 2021)
- Investors on record: 9

## About

Evox Therapeutics Limited, based in the UK, focuses on developing innovative therapeutics for severe neurological diseases utilizing its proprietary ExoEdit™ technology, aimed at addressing significant unmet medical needs in this critical healthcare sector.Founded in 2016 in Oxford, UK, Evox Therapeutics Limited specializes in exosome-based therapeutics for treating neurological disorders. The firm has engaged in 5 deals, with the most recent funding round being a Series C in February 2021, where it raised GBP 69.2 mn led by Redmile Group. The company is led by CEO Antonin de Fougerolles, who continues to guide its strategic direction.Evox Therapeutics specializes in innovative therapeutics aimed at treating severe neurological and neurodegenerative diseases through its proprietary ExoEdit™ technology. The core product offerings involve an advanced CRISPR/Cas-based gene editing system encapsulated within exosome-based nanoparticles, allowing for targeted gene knockdown of mutations associated with various neurological disorders. This addresses critical areas of unmet medical need, focusing on providing transformative treatment options for patients suffering from life-threatening conditions, primarily targeting markets in North America and Europe.In the most recent year, 2023, Evox Therapeutics reported a revenue of GBP 11,464,568.90 and an EBITDA of GBP -20,934,752.90. The company operates on a partnership model, generating revenue through strategic collaborations with biopharmaceutical companies and research institutions, facilitating the advancement of its product pipeline.Evox Therapeutics is dedicated to advancing its exosome-based therapeutics pipeline, particularly through the continuation of its DeliverEX platform aimed at rare diseases. The recent Series C funding, raised in February 2021, will support these initiatives, ensuring the progression of multiple therapeutic candidates. The company is also looking to expand into new markets, specifically targeting North America and Europe for broader outreach in delivering treatments for neurological disorders.

## Funding rounds

- Series C, Feb 18, 2021, $97M — OrbiMed Advisors, Invus [DUP], GV, Redmile Group, Eli Lilly & Company, Oxford Sciences Enterprises, Cowen Healthcare Investments
- Series B, Aug 31, 2018, $46M — Healthcare Royalty Partners, Borealis Ventures, GV, Redmile Group, Oxford Sciences Enterprises
- Series A, Apr 6, 2016, $14M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A, Series B, Series C
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Invus [DUP] — Series C
- Eli Lilly & Company — Series C
- Cowen Healthcare Investments — Series C